BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Interstellar comet 3I/ATLAS to pass closest to Earth on Friday - 2Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
- 3Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- 4Exploring the Gig Economy: Illustrations from Consultants
- 5RFK Jr.'s handpicked vaccine panel just voted to stop recommending hepatitis B shots for all newborns. Why experts object.
- The most effective method to Go Down Abundance through Ages with Disc Rates
- Help Your Efficiency with These Work area Updates
- Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- Two Indonesian UN peacekeepers killed in explosion in Lebanon
- Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
- Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- Flu season is just beginning, but doctors are already on high alert
- Manual for 6 Hot Brilliant Beds
- SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year
